RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
Friday, 28 March 2025 () MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, announced today that a new human pharmacokinetic (PK) data abstract was presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting on March 27 – 29, 2025 in Tampa, FL: ePoster P379. The abstract provides new human PK data relevant to R
Friday, 28 March 2025 ()
